Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
J.B.A.G. Haanen,J. Larkin,T.K. Choueiri,L. Albiges,B.I. Rini,M.B. Atkins,M. Schmidinger,K. Penkov,E. Michelon,J. Wang,M. Mariani,A. di Pietro,R.J. Motzer
DOI: https://doi.org/10.1016/j.esmoop.2023.101210
IF: 6.883
2023-04-27
ESMO Open
Abstract:Immunotherapy-based regimens can have varying efficacy benefits in patients with advanced renal cell carcinoma. Patient outcomes can vary based on IMDC risk. Follow-up from the JAVELIN Renal 101 trial confirms the efficacy and safety of first-line avelumab + axitinib versus sunitinib. Avelumab + axitinib had a positive benefit-to-risk ratio versus sunitinib across all IMDC risk groups. Long-term treatment with avelumab + axitinib did not result in new safety signals, and AEs decreased over time. We report updated data for avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma from the third interim analysis of the phase III JAVELIN Renal 101 trial. Progression-free survival (PFS), objective response rate (ORR), and duration of response per investigator assessment (RECIST version 1.1) and overall survival (OS) were evaluated in the overall population and in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups; safety was also assessed. Overall, median OS [95% confidence interval (CI)] was not reached [42.2 months-not estimable (NE)] with avelumab plus axitinib versus 37.8 months (31.4-NE) with sunitinib [hazard ratio (HR) 0.79, 95% CI 0.643-0.969; one-sided P = 0.0116], and median PFS (95% CI) was 13.9 months (11.1-16.6 months) versus 8.5 months (8.2-9.7 months), respectively (HR 0.67, 95% CI 0.568-0.785; one-sided P < 0.0001). In patients with IMDC favorable-, intermediate-, poor-, or intermediate plus poor-risk disease, respectively, HRs (95% CI) for OS with avelumab plus axitinib versus sunitinib were 0.66 (0.356-1.223), 0.84 (0.649-1.084), 0.60 (0.399-0.912), and 0.79 (0.636-0.983), and HRs (95% CIs) for PFS were 0.71 (0.490-1.016), 0.71 (0.578-0.866), 0.45 (0.304-0.678), and 0.66 (0.550-0.787), respectively. ORRs, complete response rates, and durations of response favored avelumab plus axitinib overall and across all risk groups. In the avelumab plus axitinib arm, 81.1% had a grade ≥3 treatment-emergent adverse event (TEAE), and incidences of TEAEs and immune-related AEs were highest <6 months after randomization. Avelumab plus axitinib continues to show improved efficacy versus sunitinib and a tolerable safety profile overall and across IMDC risk groups. The OS trend favors avelumab plus axitinib versus sunitinib, but data remain immature; follow-up is ongoing. ClinicalTrials.gov NCT02684006 ; https://clinicaltrials.gov/ct2/show/NCT02684006
oncology